NLS Pharmaceutics Completes Initial $500K Financing to Advance Kadimastem Merger
Summary: NLS Pharmaceutics Ltd, a biotechnology company developing a dual orexin agonist platform, announced the completion of the initial $500,000 closing of a $1 million financing agreement with an accredited investor. The agreement, executed at $3.10 per share—48% above the market closing price prior to the company’s extraordinary general meeting—does not include warrants. This financing,…